Mirus Bio Cell & Gene Tech Expo August 2026: Gene Therapy

Scaling lentiviral vector manufacturing to large bioreactors often introduces unexpected bottlenecks that can jeopardize batch consistency and yield. As production volumes expand, traditional transfection workflows force operators to race against tight time constraints and manage unwieldy complex volumes—increasing the risk of costly process variability.

In this presentation, Dr. Lauren Kinner from Miris Bio explores an innovative approach to overcoming these critical scale-up challenges. Discover how addressing transfection complex stability can streamline your upstream workflow, optimize raw material usage, and bring greater reliability to large-scale viral vector production. Watch the full video to see the data and learn how to simplify your lentivirus manufacturing process.

About Mirus Bio:

Mirus Bio is a long-standing leader in the field of gene delivery technology. In addition to offering world-class transfection and electroporation products for basic research, we now focus on providing solutions for therapeutic viral vector production, protein production and CRISPR genome editing. Our most recent breakthrough product line of TransIT-VirusGEN® Transfection Regents provide superior titers for small-to-large scale production of AAV and lentiviral vectors, supporting gene therapy.